Hepatitis D virus infection in persons with HIV and hepatitis B virus across Europe : A cross‐sectional analysis of the HDV‐Europe cohort

INTRODUCTION: Infection with hepatitis D virus (HDV) is known to accelerate the progression of liver disease and is associated with mortality in individuals with HIV and hepatitis B virus (HBV). However, little is known about current HDV epidemiology, including HDV-testing practices and prevalence, in this population in Europe. METHODS: We conducted a cross-sectional study of clinical cohorts across Europe (Germany, Italy, the Netherlands, Poland, Spain, Switzerland and United Kingdom). Included individuals were those living with HIV, ever hepatitis B surface antigen positive, aged ≥18 years and actively in care on December 31, 2023. We calculated the percentage of individuals tested for HDV, prevalence of individuals who ever had anti-HDV positive serology (i.e., past/current infection) and the prevalence of individuals whose last HDV RNA result was positive (i.e., active infection). RESULTS: A total of 2970 individuals were included. Anti-HDV antibody results were available in 2189 (73.7%). Of them, 261 (12.0%) had past/current HDV infection, ranging between 3.8% in the United Kingdom and 27.3% in Poland. Among the 261 individuals with an anti-HDV-positive result, 162 (62.1%) had been tested for HDV RNA. Of them, 92 (56.8%) had active HDV infection. Of the overall population with available data, active HDV infection was observed in 4.4% (n = 92/2077), ranging between 0.9% in the Netherlands and 11.0% in Italy. CONCLUSIONS: In Europe, about one-eighth of individuals with HIV/HBV in care have evidence of past/current HDV infection, in whom half have active HDV infection. Nevertheless, these results come from a setting where one-quarter have yet to be tested for anti-HDV antibodies.

Authors

Institutions

Publication Details

Journal
HIV Medicine
Published
2026-10-15
DOI
https://doi.org/10.1111/hiv.70320
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hepatitis D virus infection in persons with HIV and hepatitis B virus across Europe : A cross‐sectional analysis of the HDV‐Europe cohort

Miłosz Parczewski, Sanjay R. Bhagani, Kathrin van Bremen, Alessandro Tavelli et al.
HIV Medicine
Hepatitis B Virus Studies
article

Hepatitis D virus infection in persons with HIV and hepatitis B virus across Europe : A cross‐sectional analysis of the HDV‐Europe cohort

Miłosz Parczewski, Sanjay R. Bhagani, Kathrin van Bremen, Alessandro Tavelli, Anders C. Boyd, Gilles Wandeler, Pablo Ryan, Juan Berenguer, Charlotte Lim, Jürgen Kurt Rockstroh, María del Mar Arcos-Rueda, Luz Martı́n-Carbonero, Charles Béguelin, Antonella d’Arminio Monforte, Iwona Cielniak, Fauzi M A Elamouri, Marc van der Valk, Magdalena Tchórz, Thomas Lutz
article en

Abstract

INTRODUCTION: Infection with hepatitis D virus (HDV) is known to accelerate the progression of liver disease and is associated with mortality in individuals with HIV and hepatitis B virus (HBV). However, little is known about current HDV epidemiology, including HDV-testing practices and prevalence, in this population in Europe. METHODS: We conducted a cross-sectional study of clinical cohorts across Europe (Germany, Italy, the Netherlands, Poland, Spain, Switzerland and United Kingdom). Included individuals were those living with HIV, ever hepatitis B surface antigen positive, aged ≥18 years and actively in care on December 31, 2023. We calculated the percentage of individuals tested for HDV, prevalence of individuals who ever had anti-HDV positive serology (i.e., past/current infection) and the prevalence of individuals whose last HDV RNA result was positive (i.e., active infection). RESULTS: A total of 2970 individuals were included. Anti-HDV antibody results were available in 2189 (73.7%). Of them, 261 (12.0%) had past/current HDV infection, ranging between 3.8% in the United Kingdom and 27.3% in Poland. Among the 261 individuals with an anti-HDV-positive result, 162 (62.1%) had been tested for HDV RNA. Of them, 92 (56.8%) had active HDV infection. Of the overall population with available data, active HDV infection was observed in 4.4% (n = 92/2077), ranging between 0.9% in the Netherlands and 11.0% in Italy. CONCLUSIONS: In Europe, about one-eighth of individuals with HIV/HBV in care have evidence of past/current HDV infection, in whom half have active HDV infection. Nevertheless, these results come from a setting where one-quarter have yet to be tested for anti-HDV antibodies.

HIV Medicine
University of Bern (CH), Universität Hamburg (DE), Royal Free London NHS Foundation Trust (GB), University of Pavia (IT), University Hospital Bonn (DE), Hospital Universitario La Paz (ES), University Hospital of Bern (CH), Hospital General Universitario Gregorio Marañón (ES), MSH Medical School Hamburg – University of Applied Sciences and Medical University (DE), Centro de Investigación Biomédica en Red (ES), Stichting HIV Monitoring (NL), Centrum für Integrierte Onkologie (DE), Amsterdam University Medical Centers (NL), Hospital Universitario Infanta Leonor (ES), Amsterdam institute for Immunology and Infectious Diseases (NL), Centro de Investigación Biomédica en Red Enfermedades Infecciosas (ES), University College London (GB), Cardinal Stefan Wyszynski University in Warsaw (PL), Pomeranian Medical University (PL), University of Amsterdam (NL)
Gilead Sciences
Good health and well-being
Openalex Percentile: Top 12%
Hepatitis B Virus Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.